Richard C Malabre insider trades: Akebia Therapeutics (AKBA) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Richard reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | AKBA | ↓ Sell10b5-1 | 49,524 | $1.39 | $69K | Direct | Feb 4, 2026 (2d) |
| Jun 9, 2025 | AKBA | ↓ Sell10b5-1 | 15,000 | $4.01 | $60K | Direct | Jun 11, 2025 (2d) |
| Jun 4, 2025 | AKBA | ↓ Sell10b5-1 | 13,334 | $3.53 | $47K | Direct | Jun 5, 2025 (1d) |
| Feb 3, 2025 | AKBA | ↓ Sell10b5-1 | 30,202 | $2.10 | $63K | Direct | Feb 4, 2025 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other AKBA insiders
Open-market trades in the last 12 months
About Richard C Malabre's insider trades
Richard C Malabre is SVP, Chief Accounting Officer at Akebia Therapeutics (AKBA). Since Feb 3, 2025, Richard has reported no open-market purchases and 4 sales worth $239K on SEC Form 4. In the last 12 months: 1 sale ($69K).
4 sales (100% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (3 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AKBA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.